Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib for Hospitalized COVID-19 Patients with Pulmonary Distress
NCT04382586Phase 2Completed
- Sponsor
- BeiGene
- Start
- Jul 2020
- Primary completion
- Feb 2021
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Zanubrutinib with Placebo (2 arms). Primary endpoints: Number of Participants With Respiratory Failure-free Survival at Day 28 and Time to Breathing Room Air at 7 months. Started Jul 2020; status: completed.
02
Drugs
zanubrutinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04382586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382586.